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Abstract
Background: Breast cancer is a heterogeneous disease associated with different patient prognosis and responses
to therapy. Vitamin D has been emerging as a potential treatment for cancer, as it has been demonstrated that it
modulates proliferation, apoptosis, invasion and metastasis, among others. It acts mostly through the Vitamin D
receptor (VDR) and the synthesis and degradation of this hormone are regulated by the enzymes CYP27B1 and
CYP24A1, respectively. We aimed to study the expression of these three proteins by immunohistochemistry in a
series of breast lesions.
Methods: We have used a cohort comprising normal breast, benign mammary lesions, carcinomas in situ and
invasive carcinomas and assessed the expression of the VDR, CYP27B1 and CYP24A1 by immunohistochemistry.
Results: The results that we have obtained show that all proteins are expressed in the various breast tissues,
although at different amounts. The VDR was frequently expressed in benign lesions (93.5%) and its levels of
expression were diminished in invasive tumours (56.2%). Additionally, the VDR was strongly associated with the
oestrogen receptor positivity in breast carcinomas. CYP27B1 expression is slightly lower in invasive carcinomas
(44.6%) than in benign lesions (55.8%). In contrast, CYP24A1 expression was augmented in carcinomas (56.0% in in
situ and 53.7% in invasive carcinomas) when compared with that in benign lesions (19.0%).
Conclusions: From this study, we conclude that there is a deregulation of the Vitamin D signalling and metabolic
pathways in breast cancer, favouring tumour progression. Thus, during mammary malignant transformation,
tumour cells lose their ability to synthesize the active form of Vitamin D and respond to VDR-mediated Vitamin D
effects, while increasing their ability to degrade this hormone.
Background
Breast cancer is one of the major causes of death by
cancer in women worldwide [1]. Nowadays, breast can-
cer is no longer considered to be a single disease, but is
rather comprised of distinct tumour subtypes displaying
different clinical outcomes [2]. Over the lifetime of the
individual, in order to a tumour to develop it needs a
combination of low-penetrance genetic factors and
environmental aspects. Ultimately, cancer results from
alterations in the control of the complex balance of pro-
liferation, differentiation and programmed cell death [3]
and these processes appear to be regulated by intrinsic
and extrinsic factors, like niche signals, hormonal and
dietary aspects, among others [4], [5].
Vitamin D is a lipid soluble substance that belongs to
the family of secosteroid hormones. Its physiological
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any medium, provided the original work is properly cited.role has been classically associated with calcium regula-
tion and phosphate transport in bone metabolism. Apart
from this endocrine role, subsequent studies have
widened the range of functions for Vitamin D and this
has been particularly important in the field of cancer
research. Several authors have demonstrated, in various
models of cancer (including the breast), the ability of
Vitamin D to perform autocrine and paracrine func-
tions. Specifically, it has been demonstrated the capacity
to modulate cancer features, namely proliferation and
differentiation [6], apoptosis [7], angiogenesis [8], inva-
sion and metastasis [9].
Vitamin D exerts most of its biological activities by bind-
ing to a specific high-affinity receptor, the Vitamin D
Receptor (VDR), that was first identified in a breast cancer
cell line in 1979 [10]. The VDR belongs to the superfamily
of nuclear receptors for steroid hormones and regulates
gene expression by acting as a ligand-activated transcrip-
tion factor [11]. Several studies have demonstrated that
the VDR knockout mice display a higher incidence rate of
carcinogen-induced preneoplastic breast lesions when
compared with their littermates [12], [13]. These reports
highlight the importance of the VDR deficiency in sensitiz-
ing the mammary gland to transformation in response to a
carcinogenic agent. Immunohistochemical studies have
confirmed that the VDR is expressed in samples from nor-
mal breast tissues [14] and also in breast cancer biopsy
specimens [15]. Because the VDR is expressed in the
mammary gland and Vitamin D has been shown to display
anticarcinogenic properties, this hormone has emerged as
a promising targeted therapy. But in order to keep the
homeostasis of the organism the amount of circulating
Vitamin D has to be tightly regulated. This is a very com-
plex process, in which the main components are the
enzymes 1a-hydroxylase/CYP27B1 (encoded by the gene
CYP27B1) and 24-hydroxylase/CYP24A1 (encoded by the
gene CYP24A1). CYP27B1 is responsible for the synthesis
of the biologically active form of Vitamin D (1,25-dihy-
droxyvitamin D), whereas CYP24A1 mediates the catabo-
lism of Vitamin D [16]. Several studies have focused their
attention in the comparison of the levels of these enzymes
in normal and tumour tissue. It has been observed that
both CYP27B1 and CYP24A1 are up-regulated in breast
tumours when compared with normal tissue. However,
deregulated expression of CYP24A1 seems to abrogate the
effects of CYP27B1, resulting in the degradation of Vita-
min D to less active metabolites [17]. In contrast, a recent
paper has demonstrated that CYP27B1 mRNA in breast
tumours is decreased in comparison with normal mam-
mary tissue [18]. Despite these findings, no reports regard-
ing the expression by immunohistochemistry of the VDR,
CYP27B1 and CYP24A1 in the mammary gland have been
described. The main purpose of this work was to perform
an immunohistochemical study of the expression of the
VDR, CYP27B1 and CYP24A1 in a comprehensive series
of human breast tissues comprised of normal breast,
benign mammary lesions, carcinomas in situ and invasive
breast carcinomas.
Methods
Patient’s selection and Tissue Microarray construction
We have studied a cohort of 379 benign lesion samples
and 189 cases of carcinomas in situ, collected from the
archives of the Pathology Department of General Hospital
of UNIMED in Araçatuba, Brazil. Three hundred and fifty
cases of invasive breast carcinomas were retrieved from
the archives of the Pathology Department of the Federal
University of Santa Catarina, Florianópolis, Brazil (161
cases) and from the Pathology Department of General
Hospital of UNIMED in Araçatuba, Brazil (189 tumour
samples). This last series of 189 invasive carcinomas con-
tains, in the same block, the aforementioned carcinomas
in situ. Additionally, 29 cases of normal breast tissue were
included in the study. The normal breast tissue, carcino-
mas in situ and invasive tumour samples were collected
between 1994 and 2004. The series of benign lesions was
collected between 2002 and 2006.
Representative areas of the different lesions were care-
fully selected on the H&E-stained sections, by 2 pathol-
ogists (DV and LAV) and marked on individual paraffin
blocks. Two tissue cores (2 mm in diameter) were
obtained from each selected specimen and precisely
deposited into a recipient paraffin block using a TMA
(Tissue Microarray) workstation (TMA builder, LabVi-
sion Corporation, USA). Several TMA blocks were con-
structed (40 for the invasive breast carcinomas, 22 for
the carcinomas in situ and 17 for the benign lesions),
each containing 24 tissue cores, arranged in a 4×6 sec-
tor. In each TMA block, at least 3 nonneoplastic breast
tissue cores were also included as controls and 1 core of
a non-breast sample (we have used testicular and liver
tissues). To homogenize the paraffin of the receptor
block and the paraffin of the cores extracted from the
donor blocks, the TMAs were kept at 37°C for 3 hours.
After construction, 2-μm tissue sections were cut and
adhered to Superfrost Plus glass slides. An H&E-stained
section from each block was reviewed to confirm the
presence of morphological representative areas of the
original lesions.
The present study has been conducted under the
national regulative law for the usage of biological speci-
mens from tumour banks, where the samples are exclu-
sively available for research purposes in the case of
retrospective studies.
Immunohistochemistry
Immunohistochemical staining for Oestrogen Receptor
(ER), HER2 and CK5 (Cytokeratin 5) was performed
Lopes et al. BMC Cancer 2010, 10:483
http://www.biomedcentral.com/1471-2407/10/483
Page 2 of 10using the streptavidin-biotin-peroxidase technique (Lab-
Vision Corporation) in each set of glass slides compris-
ing the TMAs, whereas P-cadherin (P-cad), EGFR
(Epidermal Growth Factor Receptor) and Progesterone
Receptor (PgR) used the HRP labelled polymer (Dako-
Cytomation, USA) as described elsewhere [19]. Antigen
unmasking for VDR was performed using a solution of
pepsin A (4 g/L; Sigma-Aldrich) for 30 minutes at 37°C.
Epitope retrieval for CYP27B1 and CYP24A1 was per-
formed using a dilution of 1:100 of citrate buffer, pH =
6.0 (Vector Laboratories, Burlingame, CA, USA) at 98°C
for 30 minutes. The antigen retrieval times, antibodies,
dilutions and suppliers are listed in Table 1. Primary
antibody incubation was performed overnight at 4°C for
VDR and CYP24A1 and for 1 h at room temperature
for CYP27B1. After washes, the slides were incubated
with secondary antibody associated with HRP labelled
polymer (ImmunoLogic, The Netherlands) for VDR or
incubated with biotinylated secondary antibody (Santa
Cruz, USA) followed by streptavidin-conjugated peroxi-
dase (Labvision) during 15 min for CYP24A1 and
CYP27B1, and immediately revealed with DAB (Dako-
Cytomation). Tissues were then counterstained with
Mayer’s haematoxylin, dehydrated and cover-slipped
u s i n gap e r m a n e n tm o u n t i n gs o l u t i o n( Z y m e d ,U S A ) .
Positive and negative controls were included in each run
in order to guarantee the reliability of the assays. Paraf-
fin sections of a basal cell carcinoma of the skin, normal
colon and normal liver were used as positive controls for
VDR, CYP27B1 and CYP24A1 expression, respectively.
Scoring and statistical analysis
The evaluation of the immunohistochemical results was
performed by three pathologists (FS, FM and LAV). VDR
nuclear expression was evaluated using the H-score
method: intensity ranked from 1 to 3 (1 - weak, 2 - mod-
erate, 3 - strong), and extension ranked from 1 to 10 (1 -
0-10% cells, 2 - 11-20% cells and so on, until a maximum
score of 10) [20]. The scores for intensity and extension
were multiplied and the following criterion was applied:
the cases were considered negative when ranging from 1
to 4; samples ranking from 5 to 30 were considered to be
positive. Considering the lack of previous reports for the
immunohistochemical evaluation of the CYP27B1 and
CYP24A1, we considered the cases to be positive only
when cytoplasmic staining was observed. The other
markers were scored as described in previous studies
from our group [19], [21].
The Statview 5.0 software package (SAS Institute,
USA) was used for all statistical analysis. Correlations
between discrete variables were performed using the
chi-square test and analysis of variance was employed to
search for associations between continuous and discrete
variables. In all analyses, a p value < 0.05 was considered
to be statistically significant.
Cell culture and Western blotting
MDA-MB-231 breast cancer cells were grown in com-
plete Dulbecco’s Modified Eagle Medium (DMEM) in
the presence of 10% foetal bovine serum (Invitrogen,
USA). Treatments with Vitamin D 100 nM (Cayman
Chemical, USA) and ethanol (vehicle) were performed
for 72 h, while the treatment with PTH (Parathyroid
Hormone) (Sigma-Aldrich, Germany) 100 nM and water
(vehicle) were performed for 4 h. Total cell lysates were
obtained and the samples were separated in an SDS-
polyacrylamide gel. After blotting into a nitrocellulose
membrane (GE Healthcare Life Sciences, UK), staining
for CYP27B1 and CYP24A1 was performed using the
antibodies (Santa Cruz, USA) presented on Table 1
overnight at a dilution of 1:200. After washes, the mem-
branes were incubated with a mouse anti-goat HRP sec-
ondary antibody (Santa Cruz) and were revealed with
ECL (GE Healthcare Life Sciences).
RNA extraction and Real-time PCR
RNA was extracted from formalin-fixed paraffin-
embedded breast lesions using the RecoverAll Total
Nucleic Acid Isolation Kit (Ambion, USA), according to
the manufacturer’s protocol. After extraction, RNA was
quantified using NanoDrop spectrophotometer (Thermo
Scientific, USA). cDNA was synthesized using the
Omniscript Reverse Transcription kit (Qiagen, Germany)
following the manufacturer’s instructions. Finally, real-
time PCR was performed using TaqMan Gene Expres-
sion Assays (Applied Biosystems, USA), using 2 mL of
cDNA and in accordance to the manufacturer’s protocol.
The TaqMan Gene Expression Assays used were
Hs00172113_m1 (VDR), Hs00168017_m1 (CYP27B1)
and Hs00167999_m1 (CYP24A1). Reactions were per-
formed using standard cycle parameters on an ABI
PRISM Sequence 7000 Detection System (Applied
Table 1 Sources and dilutions of primary antibodies related to the Vitamin D metabolism used in this study for
immunohistochemistry
Antibody Clone Manufacturer Time of incubation (min) Dilution Antigen retrieval (min)
VDR 9A7gE10.4 Calbiochem, Germany overnight 1:50 30
CYP27B1 C12 Santa Cruz, USA 60 1:200 30
CYP24A1 C18 Santa Cruz, USA overnight 1:75 30
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Page 3 of 10Biosystems). Relative transcript levels were determined
using Human GAPDH Endogenous Control (Applied
Biosystems) as an internal reference. Differences between
the breast tissue samples were determined using com-
parative delta CT method [22]. All reactions were done in
triplicate and expressed as mean of the values from three
separate experiments.
Results
VDR, CYP27B1 and CYP24A1 immunohistochemical
staining
The expression patterns of the VDR, CYP27B1 and
CYP24A1 have been evaluated by immunohistochemistry
in 947 breast tissue samples arranged in 79 TMAs. From
this set of cases, some samples could not be assessed due
to the fact that either the core had fallen out or it did not
have enough biological material to study. In all TMAs,
positive and negative cases were obtained for each protein.
The immunostainings for these markers had been pre-
viously validated in whole tissue sections with an overall
agreement of 90%. A panel with representative immunos-
tainings for each protein in different breast tissues is
s h o w ni nF i g u r e1 .W eh a v eo b s e r v e dt h a tt h eV D R
displays nuclear staining, as would be expected from a
nuclear receptor which acts as a transcription factor. Con-
sidering CYP27B1 and CYP24A1 expression, nothing has
ever been described on their expression status in the
mammary gland, as far as we know. This is the first report
showing the expression of these two enzymes in breast
lesions. These proteins present cytoplasmic and granular
staining, which could reflect their mitochondrial localisa-
tion. All proteins (VDR, CYP27B1 and CYP24A1) have
been found to be expressed in all lesions studied and also
in the normal breast tissue, although at different levels.
The differential expression of CYP27B1 and CYP24A1
was technically validated. MDA-MB-231 breast cancer
cells have been treated with PTH 100 nM and Vitamin
D 100 nM and total cell lysates have been extracted.
Western blotting analysis has confirmed the expression
of CYP27B1 and CYP24A1 upon treatment with the
aforementioned hormones (Additional file 1: Figure S1).
Additionally, using a group of randomly selected tissue
samples, RNA was isolated and used in real-time PCR
to confirm the immunohistochemical results (Additional
file 2: Table S1). Our results have shown that positive
cases in the TMAs displayed cDNA amplification in the
real-time PCR and the opposite situation was observed
for cases where no staining was present in the TMAs.
Expression of the VDR, CYP27B1 and CYP24A1 in
benign lesions of the mammary gland
In order to study the VDR, CYP27B1 and CYP24A1
expression in benign lesions of the mammary gland, we
have evaluated 379 cases arranged in 17 TMAs. The
series consisted of a variety of breast lesions, namely
usual and atypical ductal hyperplasias (UDH represent
20.1%, corresponding to 76 samples; while ADH repre-
sent 5.4%, corresponding to 21 samples), columnar cell
lesions (CCL - 25.6% of cases, corresponding to 97 sam-
ples), papillomatosis (16.9% of cases, corresponding to
64 samples) and adenosis (17.2% of cases, corresponding
to 65 samples). The percentage of immunoreactive cases
for the VDR was very high (93.5%, corresponding to 259
cases out of 277). Regarding the expression of CYP27B1,
we have observed 55.8% of positive cases, corresponding
to 173 lesions out of 310. Concerning CYP24A1 expres-
sion, we have detected 62 positive cases out of 327 sam-
ples (19.0%). Amongst all lesions, ADH cases were
overall less immunoreactive to the three proteins.
We have correlated the histological classification of
the benign lesions with the VDR, CYP27B1 and
CYP24A1 expression, but no significant associations
have been found (see Table 2 for further details).
Expression of the VDR, CYP27B1 and CYP24A1 in breast
carcinomas in situ
A fully characterized series of 189 breast carcinomas
in situ arranged in 22 TMAs was assessed for the
expression patterns of VDR, CYP27B1 and CYP24A1.
For the VDR, we have observed that 62 cases out of 131
cases (47.3%) displayed staining for this protein. Con-
cerning CYP27B1 expression, we have encountered posi-
tive staining in 66.4% of the cases (91 out of 137
samples); whereas CYP24A1 expression was observed in
56.0% of the tumours (70 out of 125 cases).
We have also assessed the expression of other breast
cancer biomarkers in our cohort (ER, HER2 and PgR and
b a s a lm a r k e r sa sd e f i n e db yo u rg r o u p[ 1 9 ]a n do t h e r s
[23]) and looked for the existence of correlations between
the expression of the Vitamin D partners and these mole-
cular markers (Table 3). ER expression has been observed
in 117 cases (61.9%), HER2 protein was present in 37
cases (15.6%) and PgR expression was detected in 90 cases
(47.6%). We have also tested our series for basal markers
and have obtained the following results: EGFR expression
is present in 10 cases (5.3%), CK5 is positive in 15 cases
(7.9%) and P-cadherin was observed in 36 samples
(19.0%). Expression of the VDR correlated positively with
ER status (p = 0.0227), with a higher percentage of VDR-
positive cases among the ER-positive tumours - 74.2% (46
out of 62 cases). Additionally, we have seen that there is
an inverse correlation between the expression of the VDR
and P-cadherin (p = 0.0078). CYP27B1 expression only
presented an inverse correlation (p = 0.0295) with EGFR
expression, but the number of cases positive for EGFR was
very low. No statistically significant associations have been
observed between CYP24A1 expression and the markers
studied.
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mammary carcinomas
We have evaluated 350 cases of invasive breast carcinomas
arranged in 40 TMAs. The cohort corresponds to 189
cases of the series for which there was an in situ compo-
nent in the adjacent area of the invasive tumour and an
additional series of 161 cases of invasive breast carcino-
mas. Positive staining for the VDR has been observed in
56.2% of the cases (172 out of 306 cases). Regarding
CYP27B1 expression, 44.6% of cases were positive
(123 out of 276 samples), whereas 53.7% of cases (151 out
of 281 tumours) presented positivity for CYP24A1.
Next, we searched for associations between the
expression of Vitamin D partners and the expression of
the molecular markers mentioned in the previous sec-
tion (Table 4). We have obtained 197 cases (56.3%)
positive for ER, 70 cases (20%) for HER2 and 143 cases
(40.9%) for PgR. As for basal markers, we have observed
that 13 cases (3.7%) were positive for EGFR expression,
48 cases (13.7%) presented positivity for CK5 and 93
cases (26.6%) stained for P-cadherin.
A statistically significant association was observed
between the VDR-positive cases and ER-positive cases
(p = 0.0002). Additionally, VDR-positive cases have also
been significantly correlated with HER2-negative cases
(p = 0.0238), but this is probably due to the low number
of positive cases for HER2 in our series of mammary
carcinomas. CYP27B1 expression presented no signifi-
cant associations with any of the markers analyzed. PgR
was the only marker that displayed an inverse correla-
tion with CYP24A1: specifically, cases positive for PgR
were mostly negative for CYP24A1 (p = 0.0485).
The series of 189 tumours with both components
(carcinomas in situ and the corresponding invasive
tumour) allowed the evaluation of the expression of the
VDR, CYP27B1 and CYP24A1 simultaneously in the
Table 2 VDR, CYP27B1 and CYP24A1 expression in the various types of benign breast lesions
VDR CYP27B1 CYP24A1
+ (%) - (%) + (%) - (%) + (%) - (%)
Usual ductal hyperplasia 84 (92.3) 7 (7.7) 57 (55.9) 45 (44.1) 23 (20.5) 89 (79.5)
Atypical ductal hyperplasia 9 (81.8) 2 (18.2) 4 (36.4) 7 (63.6) 1 (7.1) 13 (92.9)
Columnar cell lesions 63 (95.5) 3 (4.5) 43 (55.8) 34 (44.2) 13 (16.5) 66 (83.5)
Papillomatosis 45 (95.7) 2 (4.3) 30 (56.6) 23 (43.4) 9 (17.0) 44 (83.0)
Adenosis 49 (92.5) 4 (7.5) 32 (55.2) 26 (44.8) 13 (22.0) 46 (78)
p value 0.4847 0.7994 0.6842
Table 3 VDR, CYP27B1 and CYP24A1 and other breast cancer biomarkers expression in carcinomas in situ
VDR CYP27B1 CYP24A1
+ (%) - (%) + (%) - (%) + (%) - (%)
ER + (%) 46 (35.1) 38 (29.0) 58 (42.3) 29 (21.2) 41 (32.8) 36 (28.8)
- (%) 16 (12.2) 31 (23.7) 33 (24.1) 17 (12.4) 29 (23.2) 19 (15.2)
p value 0.0227 ns ns
HER2 + (%) 9 (6.9) 14 (10.7) 18 (13.1) 7 (5.1) 9 (7.2) 12 (9.6)
- (%) 53 (40.5) 55 (42.0) 73 (53.3) 39 (28.5) 61 (48.8) 43 (34.4)
p value ns ns ns
PgR + (%) 35 (26.7) 30 (22.9) 49 (35.8) 18 (13.1) 38 (30.4) 22 (17.6)
- (%) 27 (20.6) 39 (29.8) 42 (30.7) 28 (20.4) 32 (25.6) 33 (26.4)
p value ns ns ns
CK5 + (%) 3 (2.3) 8 (6.1) 7 (5.1) 4 (2.9) 8 (6.4) 4 (3.2)
- (%) 59 (45.0) 61 (46.6) 84 (61.3) 42 (30.7) 62 (49.6) 51 (40.8)
p value ns ns ns
EGFR + (%) 1 (0.8) 5 (3.8) 2 (1.5) 5 (3.7) 5 (4.0) 3 (2.4)
- (%) 61 (46.6) 64 (48.9) 89 (65.0) 41 (29.9) 65 (52.0) 52 (41.6)
p value ns 0.0295 ns
P-cad + (%) 4 (3.1) 16 (12.2) 14 (10.2) 12 (8.8) 16 (12.8) 7 (5.6)
- (%) 58 (44.3) 53 (40.5) 77 (56.2) 34 (24.8) 54 (43.2) 48 (38.4)
p value 0.0078 ns ns
ns: not significant.
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results obtained show that the three proteins (VDR,
CYP27B1 and CYP24A1) display a statistically signifi-
cant correlation of expression between the two sections
(carcinomas in situ and the matching invasive tumour).
Thus, positive cases in the in situ component are also
positive in the invasive component and the same is
observed for the negative cases.
Expression of the VDR, CYP27B1 and CYP24A1 according
to the type of breast lesion
The frequencies of protein expression of the VDR,
CYP27B1 and CYP24A1 in the different mammary tis-
sues are shown in Figure 2. The normal mammary
gland (29 cases), as expected, is positive for the expres-
sion of the VDR in all the cases studied (100%). The
majority of the samples also displays immunostaining
for CYP27B1 (63.6%) and, in contrast, the levels of
expression of CYP24A1 are low (29.6%). The VDR is
also highly expressed in benign lesions (93.5%) with a
reduction in the percentage of positive cases in carcino-
mas in situ (47.3%) and in invasive carcinomas (56.2%).
CYP27B1 expression does not vary greatly between the
different breast lesions. However, between in situ and
invasive carcinomas, a statistically significant decrease in
the percentage of positive cases was observed (from
66.4% in carcinomas in situ to 44.6% in invasive carcino-
mas). In contrast, the expression of CYP24A1 is
increased in carcinomas (56.0% in carcinomas in situ
and 53.7% in invasive carcinomas) compared with the
benign lesions (19.0%), which are mostly negative.
Discussion
Vitamin D mediates anti-proliferative and pro-differen-
tiation signalling in various epithelial tissues, including
Table 4 VDR, CYP27B1 and CYP24A1 and other breast cancer biomarkers expression in invasive breast tumours
VDR CYP27B1 CYP24A1
+ (%) - (%) + (%) - (%) + (%) - (%)
ER + (%) 114 (37.3) 60 (19.6) 70 (25.4) 86 (31.2) 93 (33.1) 66 (23.5)
- (%) 58 (19.0) 74 (24.2) 53 (19.2) 67 (24.3) 58 (20.6) 64 (22.8)
p value 0.0002 ns ns
HER2 + (%) 26 (8.6) 34 (11.3) 31 (11.4) 25 (9.2) 29 (10.4) 30 (10.8)
- (%) 144 (47.7) 98 (32.5) 90 (33.1) 126 (46.3) 121 (43.5) 98 (35.3)
p value 0.0238 ns ns
PgR + (%) 71 (23.3) 59 (19.3) 52 (18.8) 64 (23.2) 71 (25.3) 46 (16.4)
- (%) 100 (32.8) 75 (24.6) 71 (25.7) 89 (32.2) 80 (28.5) 84 (29.9)
p value ns ns 0.0485
CK5 + (%) 27 (8.8) 19 (6.2) 15 (5.4) 24 (8.7) 27 (9.6) 16 (5.7)
- (%) 145 (47.4) 115 (37.6) 108 (39.1) 129 (46.7) 124 (44.1) 114 (40.6)
p value ns ns ns
EGFR + (%) 4 (1.3) 7 (2.3) 4 (1.5) 6 (2.2) 6 (2.1) 3 (1.1)
- (%) 166 (54.8) 126 (41.6) 118 (43.1) 146 (53.3) 145 (51.8) 126 (45.0)
p value ns ns ns
P-cad + (%) 42 (13.8) 40 (13.1) 30 (10.9) 42 (15.2) 40 (14.3) 37 (13.2)
- (%) 129 (42.3) 94 (30.8) 93 (33.7) 111 (40.2) 110 (39.3) 93 (33.2)
p value ns ns ns
ns: not significant.
Figure 2 Percentage of positive cases for VDR, CYP27B1 and
CYP24A1 in the various types of breast samples studied.
Statistical analysis shown use normal breast as reference. An
additional result is presented comparing the number of CYP27B1
positive cases between in situ and invasive carcinomas. (ns - not
significant; * p < 0.05).
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assume that disruption of the Vitamin D signalling and
metabolic pathways may occur during tumour develop-
ment. To explore this hypothesis, we have evaluated a
cohort of 947 samples of human breast tissues for the
presence of VDR, CYP27B1 and CYP24A1. Specifically,
our series consisted of normal breast tissue (29 cases),
preneoplastic benign mammary lesions (379 cases),
carcinomas in situ (189 cases) and invasive breast carci-
nomas (350 cases). To the best of our knowledge, this is
the first time that the expression of the VDR, CYP27B1
and CYP24A1 has been evaluated in histological sec-
tions of mammary lesions.
The three proteins have been found to be expressed in
all breast tissues, although at different levels. VDR pre-
sented a nuclear localisation, as it would be expected for
a nuclear receptor, while CYP27B1 and CYP24A1
enzymes displayed cytoplasmic staining with a granular
pattern, which is consistent with their mitochondrial
localisation. The immunohistochemical results were
further validated and confirmed using quantitative real-
time PCR and Western blotting.
Some studies have demonstrated that the VDR protein
is expressed in samples from normal breast tissues and
also in breast cancer biopsy specimens [14,15,24,25].
Our results have shown that the VDR is expressed in
carcinomas. However, the percentage of positive cases
that we have obtained (47.3% in carcinomas in situ and
56.2% in invasive carcinomas) is lower than the 80% to
90% that had been previously described in the literature
[26,27]. This discrepancy can be explained by the devel-
opment of new detection techniques and the use of dif-
ferent scoring methods. In this study, we have used the
H-Score, the current method employed for other
nuclear receptors, like ER [20], whereas in previous stu-
dies the presence of any staining was marked as positive.
As far as we know, our study is the first to investigate
the immunohistochemical ex p r e s s i o no ft h eV D Ri na
range of benign lesions and carcinomas in situ of the
mammary gland. The percentage of positive cases for
the VDR is higher in benign lesions than in invasive
tumours (93.5% and 56.2%, respectively), while the carci-
nomas in situ display the lowest value of all (47.3%).
There are some studies showing higher levels of VDR in
tumour tissues [18,28], but this discrepancy can be
attributed to the use of different evaluation techniques.
An interesting finding is the correlation between the
expression of the VDR and the ER in both in situ and
invasive carcinomas. In fact, the VDR is expressed in
most ER-positive cases (54.7% in in situ carcinomas and
65.5% in invasive tumours). It is thought that one of the
VDR functions is to counteract oestrogen-mediated pro-
liferation and maintain differentiation [12]. Indeed, data
s u p p o r tt h ec o n c e p tt h a tt he anti-tumour effects of
Vitamin D and its analogues on ER-positive human
breast cancer cells are mediated through the down regu-
lation of the ER itself and the attenuation of oestrogen
responses, such as breast cancer cell growth [29,30].
Thus, being the VDR mostly expressed in ER-positive
carcinomas, Vitamin D or its analogues may become an
alternative therapy for these tumours in cases of resis-
tance to ER-targeted therapy.
The levels of protein expression of CYP27B1 and
CYP24A1 have not been previously studied in breast can-
cer. In colon cancer, a study using immunohistochemistry
has demonstrated that CYP27B1 is present at equally high
levels in normal colonic epithelium and colorectal cancer
[31]. For CYP24A1 it has been shown that increasing
amounts of this enzyme are present in normal colon tissue
and pre-malignant lesions. In cancer, the expression of
CYP24A1 decreases as a function of tumour cell dediffer-
entiation [32]. In breast tissues, McCarthy et al.[18] have
demonstrated that CYP27B1 mRNA expression was signif-
icantly down regulated in adjacent non-cancerous tissue
from women with breast cancer in comparison with indi-
viduals without cancer. Additionally, it has been shown
that the expression of mRNA for CYP27B1 and the VDR
w a sh i g h e ri nc a r c i n o m a sv e r s u sn o n - n e o p l a s t i ct i s s u e
[17]. Considering differences in expression in benign and
malignant breast tissues, we have observed an increased
expression of CYP24A1 and a decreased expression of
CYP27B1 with malignant progression. In fact, CYP27B1
was expressed in 55.8% of the preneoplastic lesions and
this percentage is decreased in invasive tumours (44.6%),
while carcinomas in situ display the highest value (66.4%)
and these differences are statistically significant. In con-
trast, CYP24A1 is augmented more than 2.5 fold in inva-
sive tumours (53.7%), compared with benign breast lesions
(19.0%) and this difference is also significant (p < 0.0001).
The in situ carcinomas exhibit the highest percentage of
positive cases (56.0%). These observations are consistent
with the results of Townsend and colleagues [17], which
have demonstrated that there was an up regulation of
CYP24A1 mRNA in breast tumour tissue, in comparison
with normal breast. It has also been described that the
CYP24A1 gene is amplified in breast cancer [33]. In con-
trast, another study has found no differences in the
expression of the VDR, CYP27B1 and CYP24A1 mRNA in
breast cancer and non-neoplastic mammary tissue [34].
These contradictory results may be explained by recent
reports where it is described that VDR and CYP24A1 are
under the post-transcriptional control of miRNAs [35,36].
Breast cancer is a process that evolves through the
accumulation of (epi)genetic events that drive uncon-
trolled proliferation and resistance to apoptosis. The
active form of Vitamin D is known for its capacity to
modulate proliferation and induce apoptosis [6]. Conse-
quently, malignant cells would need to develop
Lopes et al. BMC Cancer 2010, 10:483
http://www.biomedcentral.com/1471-2407/10/483
Page 8 of 10mechanisms to deregulate Vitamin D metabolic and sig-
nalling pathways in order to allow tumour development
[37]. Furthermore, it has been suggested that the Vitamin
D produced in non-renal tissues is not released into the
blood stream, but instead acts locally [38]. Therefore, the
amount of Vitamin D available in the tissue depends on
the relative amounts of CYP27B1 (synthesis) and
CYP24A1 (catabolism). Accordingly, our results show a
deregulation of these two enzymes in the different stages
of breast carcinogenesis. The crucial step of transforma-
tion introduces a clear unbalance in the Vitamin D sig-
nalling and metabolic pathways. A reduction in the
expression of the VDR in carcinomas indicates lower sen-
sitivity of the tissue to Vitamin D control. Furthermore, a
strong increase in CYP24A1 positive cases points to an
enhanced ability of the cells to degrade this hormone. In
contrast, the stable levels of CYP27B1 throughout the
transformation process, with only a small decrease in
invasive carcinomas, may reflect a lower capacity to
metabolize Vitamin D into its active form.
Conclusions
In summary, this is the first study to report the expres-
sion of the VDR, CYP27B1 and CYP24A1 in a series of
normal breast, preneoplastic mammary lesions, breast
carcinomas in situ and invasive tumours. We have cor-
related the expression of these Vitamin D partners with
the expression of a panel of tumour biomarkers.
Furthermore, we have confirmed these results by real-
time RT-PCR. Overall, our results on the expression of
the VDR, CYP27B1 and CYP24A1 suggest that there is
a deregulation of the Vitamin D metabolic and signal-
ling pathways in breast cancer, in order to favour
tumour progression. Thus, during breast malignant
transformation, tumour cells lose their ability to synthe-
s i z et h ea c t i v ef o r mo fV i t a m i nDa n dt or e s p o n dt o
Vitamin D effects, while increasing their ability to
degrade this hormone.
Additional material
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(1,25(OH)2D3) 100 nM for 72 h. a-tubulin was used as a loading control
Additional file 2: Table S2: VDR, CYP27B1 and CYP24A1 expression in
tumours that display both the in situ and the invasive component in the
same histological section.
List of abbreviations
VDR: Vitamin D Receptor; TMA: Tissue Microarray; ER: oestrogen receptor; CK:
Cytokeratin; EGFR: Epidermal Growth Factor Receptor; UDH: Usual Ductal
Hyperplasia; ADH: Atypical Ductal Hyperplasia; CCL: Columnar Cell Lesions
Competing interests
The authors declare that they have no competing interests.
Authors’ contributions
NL performed the practical work, analysed the data and drafted the
manuscript. BS, DM and MG participated in the practical work. DV, LAV and
FM analysed the data. JP and JLC designed the study and contributed to
the manuscript. FS conceived the study, participated in its design and
coordination, analysed the data and contributed to the manuscript. All
authors read and approved the final manuscript.
Acknowledgements
This study was supported by four research grants (Nair Lopes: SFRH/BD/
39208/2007; Diana Martins: SFRH/BD/66152/2009; Madalena Gomes: PIC/IC/
83264/2007; José Luis Costa: SFRH/BPD/20370/2004) and by a scientific
project (PIC/IC/83264/2007), both financed by Fundação para a Ciência e
Tecnologia (Portugal). Salary support was provided for Joana Paredes from
Programa Ciência 2007, also financed by Fundação para a Ciência e
Tecnologia (Portugal).
Author details
1IPATIMUP - Institute of Molecular Pathology and Immunology of the
University of Porto (Rua Dr Roberto Frias, s/n), Porto (4200-465), Portugal.
2Department of Pathology, Federal University of Santa Catarina (Campus
Reitor João David Ferreira Lima), Florianópolis (88040-970), Brazil.
3Department of Pathology, General Hospital of UNIMED (Rua Gaspar de
Lemos, 2), Araçatuba (16013-800), Brazil.
4Medical Faculty of the University of
Porto (Alameda Prof. Hernâni Monteiro), Porto (4200-319), Portugal.
Received: 20 April 2010 Accepted: 11 September 2010
Published: 11 September 2010
References
1. Ferlay J, Autier P, Boniol M, Heanue M, Colombet M, Boyle P: Estimates of
the cancer incidence and mortality in Europe in 2006. Ann Oncol 2007,
18(3):581-592.
2. Perou CM, Sorlie T, Eisen MB, van de Rijn M, Jeffrey SS, Rees CA, Pollack JR,
Ross DT, Johnsen H, Akslen LA, et al: Molecular portraits of human breast
tumours. Nature 2000, 406(6797):747-752.
3. Hanahan D, Weinberg RA: The hallmarks of cancer. Cell 2000, 100(1):57-70.
4. Huang W, Ma K, Zhang J, Qatanani M, Cuvillier J, Liu J, Dong B, Huang X,
Moore DD: Nuclear receptor-dependent bile acid signaling is required
for normal liver regeneration. Science 2006, 312(5771):233-236.
5. Thorne J, Campbell MJ: The vitamin D receptor in cancer. Proc Nutr Soc
2008, 67(2):115-127.
6. Deeb KK, Trump DL, Johnson CS: Vitamin D signalling pathways in
cancer: potential for anticancer therapeutics. Nat Rev Cancer 2007,
7(9):684-700.
7. Dusso AS, Brown AJ, Slatopolsky E: Vitamin D. Am J Physiol Renal Physiol
2005, 289(1):F8-28.
8. Mantell DJ, Owens PE, Bundred NJ, Mawer EB, Canfield AE: 1 alpha,25-
dihydroxyvitamin D(3) inhibits angiogenesis in vitro and in vivo. Circ Res
2000, 87(3):214-220.
9. Hansen CM, Frandsen TL, Brunner N, Binderup L: 1 alpha,25-
Dihydroxyvitamin D3 inhibits the invasive potential of human breast
cancer cells in vitro. Clin Exp Metastasis 1994, 12(3):195-202.
10. Eisman JA, Martin TJ, MacIntyre I, Moseley JM: 1,25-dihydroxyvitamin-D-
receptor in breast cancer cells. Lancet 1979, 2(8156-8157):1335-1336.
11. Evans RM: The steroid and thyroid hormone receptor superfamily. Science
1988, 240(4854):889-895.
12. Zinser GM, McEleney K, Welsh J: Characterization of mammary tumor cell
lines from wild type and vitamin D3 receptor knockout mice. Mol Cell
Endocrinol 2003, 200(1-2):67-80.
13. Zinser GM, Suckow M, Welsh J: Vitamin D receptor (VDR) ablation alters
carcinogen-induced tumorigenesis in mammary gland, epidermis and
lymphoid tissues. J Steroid Biochem Mol Biol 2005, 97(1-2):153-164.
14. Berger U, Wilson P, McClelland RA, Colston K, Haussler MR, Pike JW,
Coombes RC: Immunocytochemical detection of 1,25-dihydroxyvitamin D
receptors in normal human tissues. J Clin Endocrinol Metab 1988,
67(3):607-613.
Lopes et al. BMC Cancer 2010, 10:483
http://www.biomedcentral.com/1471-2407/10/483
Page 9 of 1015. Freake HC, Abeyasekera G, Iwasaki J, Marcocci C, MacIntyre I, McClelland RA,
Skilton RA, Easton DF, Coombes RC: Measurement of 1,25-
dihydroxyvitamin D3 receptors in breast cancer and their relationship to
biochemical and clinical indices. Cancer Res 1984, 44(4):1677-1681.
16. Haussler MR, Whitfield GK, Haussler CA, Hsieh JC, Thompson PD,
Selznick SH, Dominguez CE, Jurutka PW: The nuclear vitamin D receptor:
biological and molecular regulatory properties revealed. J Bone Miner Res
1998, 13(3):325-349.
17. Townsend K, Banwell CM, Guy M, Colston KW, Mansi JL, Stewart PM,
Campbell MJ, Hewison M: Autocrine metabolism of vitamin D in normal
and malignant breast tissue. Clin Cancer Res 2005, 11(9):3579-3586.
18. McCarthy K, Laban C, Bustin SA, Ogunkolade W, Khalaf S, Carpenter R,
Jenkins PJ: Expression of 25-hydroxyvitamin D-1-alpha-hydroxylase, and
vitamin D receptor mRNA in normal and malignant breast tissue.
Anticancer Res 2009, 29(1):155-157.
19. Matos I, Dufloth R, Alvarenga M, Zeferino LC, Schmitt F: p63, cytokeratin 5,
and P-cadherin: three molecular markers to distinguish basal phenotype
in breast carcinomas. Virchows Arch 2005, 447(4):688-694.
20. Bacus S, Flowers JL, Press MF, Bacus JW, McCarty KS Jr: The evaluation of
estrogen receptor in primary breast carcinoma by computer-assisted
image analysis. Am J Clin Pathol 1988, 90(3):233-239.
21. Paredes J, Lopes N, Milanezi F, Schmitt FC: P-cadherin and cytokeratin 5:
useful adjunct markers to distinguish basal-like ductal carcinomas in
situ. Virchows Arch 2007, 450(1):73-80.
22. Livak KJ, Schmittgen TD: Analysis of relative gene expression data using
real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods
2001, 25(4):402-408.
23. Nielsen TO, Hsu FD, Jensen K, Cheang M, Karaca G, Hu Z, Hernandez-
Boussard T, Livasy C, Cowan D, Dressler L, et al: Immunohistochemical and
clinical characterization of the basal-like subtype of invasive breast
carcinoma. Clin Cancer Res 2004, 10(16):5367-5374.
24. Friedrich M, Axt-Fliedner R, Villena-Heinsen C, Tilgen W, Schmidt W,
Reichrath J: Analysis of vitamin D-receptor (VDR) and retinoid X-receptor
alpha in breast cancer. Histochem J 2002, 34(1-2):35-40.
25. Segersten U, Holm PK, Bjorklund P, Hessman O, Nordgren H, Binderup L,
Akerstrom G, Hellman P, Westin G: 25-Hydroxyvitamin D3 1alpha-
hydroxylase expression in breast cancer and use of non-1alpha-
hydroxylated vitamin D analogue. Breast Cancer Res 2005, 7(6):R980-986.
26. Berger U, Wilson P, McClelland RA, Colston K, Haussler MR, Pike JW,
Coombes RC: Immunocytochemical detection of 1,25-dihydroxyvitamin
D3 receptor in breast cancer. Cancer Res 1987, 47(24 Pt 1):6793-6799.
27. Berger U, McClelland RA, Wilson P, Greene GL, Haussler MR, Pike JW,
Colston K, Easton D, Coombes RC: Immunocytochemical determination of
estrogen receptor, progesterone receptor, and 1,25-dihydroxyvitamin D3
receptor in breast cancer and relationship to prognosis. Cancer Res 1991,
51(1):239-244.
28. Friedrich M, Rafi L, Tilgen W, Schmidt W, Reichrath J: Expression of 1,25-
dihydroxy vitamin D3 receptor in breast carcinoma. J Histochem
Cytochem 1998, 46(11):1335-1337.
29. Swami S, Krishnan AV, Feldman D: 1alpha,25-Dihydroxyvitamin D3 down-
regulates estrogen receptor abundance and suppresses estrogen actions
in MCF-7 human breast cancer cells. Clin Cancer Res 2000, 6(8):3371-3379.
30. Stoica A, Saceda M, Fakhro A, Solomon HB, Fenster BD, Martin MB:
Regulation of estrogen receptor-alpha gene expression by 1, 25-
dihydroxyvitamin D in MCF-7 cells. J Cell Biochem 1999, 75(4):640-651.
31. Matusiak D, Murillo G, Carroll RE, Mehta RG, Benya RV: Expression of
vitamin D receptor and 25-hydroxyvitamin D3-1{alpha}-hydroxylase in
normal and malignant human colon. Cancer Epidemiol Biomarkers Prev
2005, 14(10):2370-2376.
32. Matusiak D, Benya RV: CYP27A1 and CYP24 expression as a function of
malignant transformation in the colon. J Histochem Cytochem 2007,
55(12):1257-1264.
33. Albertson DG, Ylstra B, Segraves R, Collins C, Dairkee SH, Kowbel D, Kuo WL,
Gray JW, Pinkel D: Quantitative mapping of amplicon structure by array
CGH identifies CYP24 as a candidate oncogene. Nat Genet 2000,
25(2):144-146.
34. de Lyra EC, da Silva IA, Katayama ML, Brentani MM, Nonogaki S, Goes JC,
Folgueira MA: 25(OH)D3 and 1,25(OH)2D3 serum concentration and
breast tissue expression of 1alpha-hydroxylase, 24-hydroxylase and
Vitamin D receptor in women with and without breast cancer. J Steroid
Biochem Mol Biol 2006, 100(4-5):184-192.
35. Mohri T, Nakajima M, Takagi S, Komagata S, Yokoi T: MicroRNA regulates
human vitamin D receptor. Int J Cancer 2009, 125(6):1328-1333.
36. Komagata S, Nakajima M, Takagi S, Mohri T, Taniya T, Yokoi T: Human
CYP24 catalyzing the inactivation of calcitriol is post-transcriptionally
regulated by miR-125b. Mol Pharmacol 2009, 76(4):702-709.
37. Kemmis CM, Welsh J: Mammary epithelial cell transformation is
associated with deregulation of the vitamin D pathway. J Cell Biochem
2008, 105(4):980-988.
38. Welsh J: Vitamin D and breast cancer: insights from animal models. Am J
Clin Nutr 2004, 80(6 Suppl):1721S-1724S.
Pre-publication history
The pre-publication history for this paper can be accessed here:
http://www.biomedcentral.com/1471-2407/10/483/prepub
doi:10.1186/1471-2407-10-483
Cite this article as: Lopes et al.: Alterations in Vitamin D signalling and
metabolic pathways in breast cancer progression: a study of VDR,
CYP27B1 and CYP24A1 expression in benign and malignant breast
lesions Vitamin D pathways unbalanced in breast lesions. BMC Cancer
2010 10:483.
Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
Lopes et al. BMC Cancer 2010, 10:483
http://www.biomedcentral.com/1471-2407/10/483
Page 10 of 10